Novel medicines for migraine prevention.
Vedana is developing a portfolio of long-acting subcutaneously dosed monoclonal antibodies targeting PACAP and other clinically emerging pathways to redefine the standard of care for migraine patients.
- Product
- Target
- Discovery
- Preclinical
- Clinical
An anti-PACAP monoclonal antibody. VDN-0100 is the foundational program in the portfolio.
A bispecific antibody targeting both PACAP and CGRP simultaneously. VDN-0200 is designed to deliver greater efficacy than targeting either pathway alone.
- VDN 0300
- Undisclosed
- The candidate is in the preclinical stage
- VDN 0400
- Undisclosed
- The candidate is in the discovery stage